CONTEMPORARY TRENDS IN THE DEVELOPMENT OF THE GLOBAL PHARMACEUTICAL INDUSTRY
DOI:
https://doi.org/10.32782/health-2026.2.8Keywords:
pharmaceutical industry, globalization of pharmaceutical markets, innovative development, digitalization, artificial intelligence, biotechnology, genomics, biosimilars, accessibility of medicines, pricing policy, pharmaceutical regulation, pharmaceutical safetyAbstract
The article examines contemporary trends in the development of the global pharmaceutical industry, which are shaped by technological innovation, the globalization of markets, transformations in the regulatory environment, and growing societal demand for the accessibility and safety of medicines. The relevance of the study is determined by the need for a comprehensive understanding of the changes affecting different components of the pharmaceutical industry and shaping the prospects for its further development. The study is based on a review-analytical examination of scientific publications, analytical materials, and regulatory documents. The methods of analysis, comparison, generalization, and synthesis were applied, which made it possible to compare the identified trends in terms of their content and to determine the relationships among them. Based on the results of the study, contemporary trends in the development of the global pharmaceutical industry were systematized into four interrelated dimensions: innovation-technological, economic, regulatory-safety, and social. For each dimension, the main characteristics, impact on industry development, key challenges, and strategic priorities were summarized. It is shown that digitalization, artificial intelligence, biotechnology, and personalized medicine are transforming the processes of drug development and manufacturing, while economic, regulatory, and social factors determine the possibilities for the practical implementation of technological changes and their impact on access to pharmacotherapy. Particular attention is paid to the development of the generic medicines and biosimilars segments, the transformation of pricing mechanisms and pharmaceutical regulation, as well as the resilience of pharmaceutical supply chains. The scientific novelty of the study lies in the comprehensive presentation of contemporary trends in pharmaceutical industry development within a unified analytical framework, which makes it possible to trace the relationship between technological changes, economic outcomes, regulatory conditions, and social consequences. The practical significance of the obtained results lies in the possibility of using the proposed systematization for a comprehensive analysis of transformations in the pharmaceutical industry, identifying its development priorities, and substantiating managerial and regulatory decisions.
References
International Federation of Pharmaceutical Manufacturers & Associations. The Pharmaceutical Industry and Global Health: Facts and Figures 2022. Geneva: IFPMA, 2022. 101 p. URL: https://www.ifpma.org/wp-content/uploads/2023/01/i2023_IFPMA-Facts-And-Figures-2022.pdf (дата звернення: 10.07.2026).
Access to Medicine Foundation. Access to Medicine Index 2024. Amsterdam: Access to Medicine Foundation, 2024. 232 p. URL: https://accesstomedicinefoundation.org/insights-resources/index-ranking#index--insights (дата звернення: 10.07.2026).
Semchenkova O. Trends Shaping the World of the Pharmaceutical Market. American Journal of Industrial and Business Management. 2025. Vol. 15. № 10. P. 1460–1469. DOI: https://doi.org/10.4236/ajibm.2025.1510077.
Miozza M., Brunetta F., Appio F. P. Digital transformation of the Pharmaceutical Industry: A future research agenda for management studies. Technological Forecasting and Social Change. 2024. Vol. 207. DOI: https://doi.org/10.1016/j.techfore.2024.123580.
Fu C., Chen Q. The future of pharmaceuticals: Artificial intelligence in drug discovery and development. Journal of Pharmaceutical Analysis. 2025. Vol. 15. P. 1–21. DOI: https://doi.org/10.1016/j.jpha.2025.101248.
European Medicines Agency. Reflection paper on the use of Artificial Intelligence (AI) in the medicinal product lifecycle. Amsterdam: EMA, 2024. 18 p. URL: https://www.ema.europa.eu/system/files/documents/scientific-guideline/reflection-paper-use-artificial-intelligence-ai-medicinal-product-lifecycle-en.pdf (дата звернення: 10.07.2026).
Haider R. The future of pharmaceuticals industry 2024. Journal of Pharmaceutics and Pharmacology Research. 2023. Vol. 6. № 5. P. 1–11. DOI: https://doi.org/10.31579/2688-7517/143.
Huanbutta K. et al. Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance. European Journal of Pharmaceutical Sciences. 2024. Vol. 203. DOI: https://doi.org/10.1016/j.ejps.2024.106938.
Martínez-Jiménez J. E. et al. A review of precision medicine in developing pharmaceutical products: Perspectives and opportunities. International Journal of Pharmaceutics. 2025. Vol. 670. DOI: https://doi.org/10.1016/j.ijpharm.2024.125070.
Anthwal A. et al. Industry 4.0 technologies adoption for digital transition in drug discovery and development: A review. Journal of Industrial Information Integration. 2024. Vol. 38. DOI: https://doi.org/10.1016/j.jii.2024.100562.
Кудирко Л. Інноваційні компанії на міжнародному ринку фармацевтичної продукції. Товари і ринки. 2025. № 1. С. 4–20. DOI: https://doi.org/10.31617/2.2025(53)01.
Rieger C., Dean J. A., Hall L., Vasquez P., Merlo G. Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review. BioDrugs. 2024. Vol. 38. № 4. P. 541–555. DOI: https://doi.org/10.1007/s40259-024-00659-0.
Morgan S. G., Bathula H. S., Moon S. Achieving fair pricing of medicines. BMJ. 2020. Vol. 368. Article l4627. DOI: https://doi.org/10.1136/bmj.l4627.
Anggriani Y., Ramadaniati H. U., Sarnianto P., Pontoan J., Suryawati S. The impact of pharmaceutical policies on medicine procurement pricing in Indonesia under the implementation of Indonesia’s social health insurance system. Value in Health Regional Issues. 2020. Vol. 21. P. 1–8. DOI: https://doi.org/10.1016/j.vhri.2019.05.005.
Joosse I. R., Tordrup D., Glanville J., Mantel-Teeuwisse A. K., van den Ham H. A. A systematic review of policies regulating or removing mark-ups in the pharmaceutical supply and distribution chain. Health Policy. 2023. Vol. 138 P. 1–9. DOI: https://doi.org/10.1016/j.healthpol.2023.104919.
Umaru O. T. et al. Global pharmaceutical regulation: comparative frameworks and operations. Pharmacy. 2026. Vol. 14. № 2. DOI: https://doi.org/10.3390/pharmacy14020050.
U.S. Food and Drug Administration. Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products: Draft Guidance for Industry and Other Interested Parties. Silver Spring: FDA, 2025. URL: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligencesupport-regulatory-decision-making-drug-and-biological?utm_source=chatgpt.com (дата звернення: 10.07.2026).
Negrila C. D., Gherasie L.-M., Armean S. M., Armean P. From legislative harmonization to real-world access: a scoping review of pharmaceutical regulation and access to medicines in Romania. Healthcare. 2026. Vol. 14. № 5. DOI: https://doi.org/10.3390/healthcare14050688.
OECD. Securing Medical Supply Chains in a Post-Pandemic World. OECD Health Policy Studies. Paris: OECD Publishing, 2024. 145 p. DOI: https://doi.org/10.1787/119c59d9-en.
Badejo O., Ierapetritou M. Enhancing pharmaceutical supply chain resilience: A multi-objective study with disruption management. Computers & Chemical Engineering. 2024. Vol. 188. DOI: https://doi.org/10.1016/j.compchemeng.2024.108769.
Goswami A., Baveja A., Ding X., Melamed B. et al. An integrated framework for modeling pharmaceutical supply chains with disruptions and risk mitigation. Annals of Operations Research. 2024. DOI: https://doi.org/10.1007/s10479-024-06381-y.
